Batiraxcept（Cat No.:I042161）is an investigational monoclonal antibody that targets the VEGF-C (vascular endothelial growth factor C), a key protein involved in the formation of new blood vessels (angiogenesis), particularly in tumors. By inhibiting VEGF-C, batiraxcept aims to disrupt the growth and spread of tumors by preventing the formation of blood vessels that supply nutrients to cancer cells. This inhibition may help reduce tumor size and metastasis. Batiraxcept is being studied in clinical trials for its potential to treat various cancers, with a focus on improving patient outcomes through anti-angiogenic therapy.
